Company Filing History:
Years Active: 2025
Title: Sean Wiedemann: Innovator in Pharmaceutical Chemistry
Introduction
Sean Wiedemann is a notable inventor based in Burlington, MA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for therapeutic use. His work exemplifies the intersection of innovation and practical application in medicine.
Latest Patents
Sean Wiedemann holds a patent for the crystalline form of deuruxolitinib phosphate. This patent, identified as polymorph Form 1 of 1H-pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d)-4-(7H-pyrrolo[2,3-]pyrimidin-4)-, (βR)-, phosphate (1:1), outlines methods of treatment using this polymorph and methods for its synthesis. This innovation is crucial for enhancing the efficacy and stability of pharmaceutical formulations.
Career Highlights
Sean Wiedemann is currently associated with Sun Pharmaceutical Industries Limited, a leading global pharmaceutical company. His role involves research and development, focusing on creating effective therapeutic solutions. His expertise in polymorph characterization has positioned him as a valuable asset in the pharmaceutical industry.
Collaborations
Due to space constraints, the collaborations section will be omitted.
Conclusion
Sean Wiedemann's contributions to pharmaceutical chemistry, particularly through his patent on deuruxolitinib phosphate, highlight his innovative spirit and commitment to advancing medical science. His work continues to impact the field positively.